Elevated serum tumor necrosis factor-alpha concentrations and bioactivity in Type 2 diabetics and patients with android type obesity

Diabetes Research and Clinical Practice

Volumn 42, Issue 3, 1998, Pages 169-174

  Winkler, G ^a   Salamon, F ^a   Harmos, G ^a   Salamon, D ^b   Speer, G ^b   Szekeres, O ^a   Hajos P ^a   Kovacs M ^b   Simon, K ^c   Cseh, K ^d  

^a ST JOHN'S HOSPITAL   (Hungary)

^b SEMMELWEIS UNIVERSITY OF MEDICINE   (Hungary)

^c St Georg's Hosp Szekesfehervar   (Hungary)

^d Karolyi Hospital   (Hungary)

Author keywords

C peptide; Insulin resistance; Obesity; Tumor necrosis factor alpha; Type 2 diabetes

Indexed keywords

C PEPTIDE; CYTOKINE; INSULIN; TUMOR NECROSIS FACTOR ALPHA;

ADULT; ARTICLE; BIOASSAY; BODY MASS; CLINICAL ARTICLE; CONTROLLED STUDY; CORRELATION FUNCTION; DIABETIC OBESITY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; IMMUNOREACTIVITY; INSULIN RESISTANCE; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; PATHOPHYSIOLOGY;

ADIPOSE TISSUE; AGED; BIOLOGICAL MARKERS; BODY MASS INDEX; C-PEPTIDE; DIABETES MELLITUS; DIABETES MELLITUS, TYPE 2; FEMALE; GLUCAGON; HUMANS; MALE; MIDDLE AGED; OBESITY; REFERENCE VALUES; TUMOR NECROSIS FACTOR-ALPHA;

EID: 0032429844     PISSN: 01688227     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0168-8227(98)00109-0     Document Type: Article

References (13)

1. Hotamisligil G.S., Spiegelman B.M. Tumor necrosis factor-α: a key component of the obesity-diabetes link. Diabetes. 43:1994;1271-1278.
2. Hotamisligil G.S., Shargill N.S., Spiegelman B.M. Adipose expression of tumor necrosis factor-alpha: direct role in obesity linked insulin resistance. Science. 259:1993;87-91.
3. Hotamisligil G.S., Peraldi P., Budaváry A., Ellis R., Wite M.F., Spiegelman B.M. IRS-1-mediated inhibition of insulin receptor tyrosine kinase activity in TNF-α- and obesity-induced insulin resistance. Science. 271:1996;665-668.
4. Stephens J.M., Lee L., Pilch P.F. Tumor necrosis factor-alfa induced insulin resistance in 3T3-L1 adipocytes is accompanied by a loss of insulin receptor substrate-1 and GLUT-4 expression without a loss of insulin receptor-mediated signal transduction. J. Biol. Chem. 272:1997;971-976.
5. Hauner H., Petruschke T., Russ M., Rochrig K., Ecker J. Effects of tumor necrosis factor alpha (TNF-alpha) on glucose transport and lipid metabolism of newly-differentiated human fett cells in cell culture. Diabetologia. 38:1995;764-771.
6. Saghizadeh M., Ong J.M., Garvey W.T., Henry R.R., Kern P.A. The expression of TNFα by human muscle. J. Clin. Invest. 97:1996;1111-1116.
7. Day C.P., Grove J., Daly A.K., Stewart M.W., Avery P.J., Walker M. Tumour necrosis factor-alpha gene promoter polymorphism and decreased insulin resistance. Diabetologia. 41:1998;430-434.
8. Uysal K.T., Wiesbrock S.M., Marino M.W., Hotamisligil G.S. Protection from obesity-induced insulin resistance in mice lacking TNF-α function. Nature. 389:1997;610-614.
9. Venter J., Doebber T., Wu M. et al. Targeted disruption of the tumor necrosis factor-α gene: metabolic consequences in obese and non obese mice. Diabetes. 46:1997;1526-1531.
10. Cseh K., Beutler B. Alternative cleavage of the cachectin/tumor necrosis factor propeptide results in a larfger inactive form of secreted protein. J. Biol. Chem. 264:1989;16256-16260.
11. Pfeiffer A., Janott J., Möhlig M. et al. Circulating tumor necrosis factor-α is elevated in male but not in female patients with Type II diabetes mellitus. Horm. Metab. Res. 29:1997;111-114.
12. Mantzoros C.S., Moschos S., Avramopoulos I. et al. Leptin concentration in relation to body mass index and the tumor necrosis factor-α system in humans. J. Clin. Endocrinol. Metab. 82:1997;3408-3413.
13. Kellerer M., Rett K., Renn W., Groop L., Häring HU Circulating TNF-alpha and leptin levels in offsprings of NIDDM patients do not correlate to individual insulin sensitivity. Horm. Metab. Res. 28:1996;737-743.